3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
46
Squamous Cell Carcinoma of Head and Neck
23
Lung Neoplasms
22
Oropharyngeal Neoplasms
13
Urinary Bladder Neoplasms
12
Nasopharyngeal Carcinoma
12
Carcinoma
11
Parkinson Disease 4, Autosomal Dominant Lewy Body
8
Biliary Tract Neoplasms
8
Uterine Cervical Neoplasms
7
Head and Neck Neoplasms
7
Pancreatic Neoplasms
6
Neoplasms
6
Esophageal Squamous Cell Carcinoma
6
Colorectal Neoplasms
6
Cholangiocarcinoma
6
Small Cell Lung Carcinoma
5
Neoplasm Metastasis
5
Mouth Neoplasms
5
Endometrial Neoplasms
5
Stomach Neoplasms
4
Laryngeal Neoplasms
4
Esophageal Neoplasms
4
Carcinoma, Squamous Cell
4
Ovarian Neoplasms
3
Neoplasms by Site
3
Mesothelioma, Malignant
3
Lymphoid Interstitial Pneumonia
3
Hypopharyngeal Neoplasms
3
Carcinoma, Transitional Cell
3
Interventions
pembrolizumab
1
enfortumab vedotin
1
Radiation Dose Hypofractionation
1
Mitomycin
1
Gemcitabine
1
Fluorouracil
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urogenital Diseases
×
Cisplatin
×
30 days
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled